Loading...

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Focus on Drug Prices Continues Amid Uncertainty Over Potential Changes

2021-08-19T12:29:37-04:00Cell & Gene Therapy, Thought Leadership|

High prescription drug prices continue to be of concern at the federal level. Despite proposed changes to drug pricing policy by the administration and HHS, industry experts question whether any significant changes will occur in the near future. Precision’s Ryan Cox and Erin Lopata weigh in on the factors contributing to the uncertainty about drug policy pricing changes.

(more…)

What Do Employers Need to Know About Specialty Drugs?

2021-08-09T17:36:25-04:00Cell & Gene Therapy, Thought Leadership|

Specialty drugs make up the bulk of the pharma pipeline. These drugs continue to come onto the market with higher and higher price tags, so employers should become more familiar with these therapies in order to properly manage them. Precision’s Erin Lopata and Jorge Font weigh in on the other considerations beyond cost that employers need to know for managing specialty drugs.

(more…)

White Paper: Engaging With Integrated Delivery Networks to Address the Social Determinants of Health

2021-04-29T17:07:11-04:00Thought Leadership|

Increasingly, stakeholders across the healthcare continuum are recognizing the importance of social determinants of health (SDOH) on outcomes and quality of life.

In this white paper from Precision’s Maureen Hennessey, we use the results of a 2019 PRECISIONvalue survey and a subsequent 2020 post-onset of COVID-19 survey to evaluate perspectives on SDOH and assess the progress of programs to address SDOH.

(more…)

Cell and gene therapy: the impact of skills gaps in a fast-growing sector

2021-04-19T17:08:39-04:00Cell & Gene Therapy, Thought Leadership|

The growing skills gaps in cell and gene therapy have resulted in a bottleneck preventing potentially revolutionary treatments from reaching the patients who need them. Phil Massey and Daniel Foody of Project Farma, part of the Precision ADVANCE collective, weigh in on the effects of the talent gap, and discuss strategies for closing the gap.

(more…)

White Paper: Developing Advanced Therapies: Considerations for Internal Versus External Manufacturing

2021-04-01T10:54:58-04:00Cell & Gene Therapy, Thought Leadership|

Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.

This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).

(more…)

How To Calculate Viral Vector Yields: A Critical Component Of The “Make vs Buy” Analysis

2021-03-03T14:49:16-05:00Cell & Gene Therapy, Thought Leadership|

Calculating viral vector yields is essential to determine how much drug product is needed for a specific gene therapy. It’s a critical analysis for any gene therapy organization looking to scale from preclinical to clinical to commercial. Project Farma’s Tony Khoury, Christian Hermanas and Salome Philip provide an in depth review of a valuable yield calculation tool that can serve as a vital prerequisite of the “make vs buy” analysis.

(more…)

Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing

2021-03-08T16:59:46-05:00Cell & Gene Therapy, Thought Leadership|

Although clinical trials in the cell and gene therapy space have skyrocketed, there’s a significant shortfall in the skilled talent required to execute on the exponential potential of cell and gene therapies. Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury discuss the biotherapeutic process and manufacturing talent gap, and propose a multipronged approach to addressing the problem through internal innovation and the external influence of academia and industry associations.

(more…)

Load More Posts